Celgene Corp (CELG)

ihacvet (73.98) Submitted: 2/06/07 6:51 PM : Start Price: $54.79 CELG Score: 43.43

Revlimid has only been approved for 6 months now and many new cancers, blood disorders, and other immune related diseases are in trials with Revlimid for future approval of this drug to treat them. Similar

Report this Post Replies: 1 | Reply | Permalink

NetscribeBiotech (76.22) Submitted: 2/22/07 2:19 AM : Start Price: $54.55 CELG Score: -44.57

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for ENL and multiple myeloma, Revlimid for myelodysplast...

Report this Post Replies: 1 | Reply | Permalink

52elgaejp (< 20) Submitted: 11/27/06 9:14 AM : Start Price: $54.83 CELG Score: 40.26

One of the fastest growing biotechs with relatively recent approval of Revlimid, which, I believe will be rapidly accepted and will have increasing indications shortly. Analysts have not fully priced in the implications of these increasing indicatio...

Report this Post Replies: 0 | Reply | Permalink

predfern (< 20) Submitted: 9/15/06 4:53 AM : Start Price: $40.93 CELG Score: 79.42

Revlimid growth for treatment of myeloma, mds and other cancers (18%).
Thalomid used for treatment of varions cancers and leprosy (59%).
Alkeran and Focalin (10%) myeloma and ovarian cancer, attention deficit hyperactivity disorder, resp.
Cash flow $...

Report this Post Replies: 0 | Reply | Permalink

Firesale (85.79) Submitted: 10/04/07 3:13 PM : Start Price: $71.93 CELG Score: 17.42

The Fight Against Cancer

Since 1988 Celgene received FDA approved for Thalomid to treat leprosy-related conditions and multiple myeloma (MM). Thalomid is being studied in numerous clinical trials for the treatment of myelodysplastic syndrome (MDS), ...

Report this Post Replies: 0 | Reply | Permalink

klip1 (< 20) Submitted: 8/23/06 11:14 PM : Start Price: $41.87 CELG Score: 73.75

CELG is a tranformational biotech company that now has 2 successful hemotological cancer drugs on the market: Revlimid and Thalomid. CELG has had an impressive run over the past 5 years but is just now showing explosive earnings growth in conjunction...

Report this Post Replies: 0 | Reply | Permalink

justahistorian (78.71) Submitted: 2/23/07 12:07 PM : Start Price: $55.61 CELG Score: 41.60

Their two primary drugs, Thalmid and Revlimid, have gained wide acceptance and they've done a good job of getting MDs on board to prescribe the drug. They have a strong vision of growth with a promising pipeline.

Report this Post Replies: 0 | Reply | Permalink

njbrit (< 20) Submitted: 1/03/08 12:53 PM : Start Price: $49.30 CELG Score: 58.02

clear leader in this sector in terms of money mgt. definite LT winner - low debt, rising BV, rev growth. CON: - 3 figure P/E

Report this Post Replies: 0 | Reply | Permalink

Whoop04 (< 20) Submitted: 10/13/06 9:34 PM : Start Price: $45.90 CELG Score: 63.29

10/2006

94

Earnings Per Share (EPS) Rating    
97
Relative Price Strength (RS) Rating    
88
Industry Group Relative Strength (Grp RS) Rating    
A-
Sales + Profit Margins + ROE (SMR) Rating    
A
Accumulation/ Distribution (Acc/Dis) Rating
B-

Report this Post Replies: 0 | Reply | Permalink

jseymour43 (< 20) Submitted: 8/23/06 9:13 PM : Start Price: $41.87 CELG Score: -73.75

Had its run and will fall out of favor with investors.

Report this Post Replies: 0 | Reply | Permalink